Locust Walk Insights

LOCUST WALK INSIGHTS

To Tax, or Not to Tax, That is the Question.

The first half of 2017 has been relatively strong for the medical technology space.  In the public sector, MedTech stocks have been performing well.  Many believe this stems from the potential permanent repeal of the Affordable Care Act and its associated medical...

Biotalk, Episode 4: Stuart Kliman, Vantage Partners

In this Episode of Biotalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Stuart Kliman (skliman@vantagepartners.com), Founder and Partner at Vantage Partners, a global management consulting firm that specializes in the areas of negotiation and relationship...

Q2 2017 Trends in Life Science Finance

Our Q2 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: Biopharma public indices Biopharma IPOs Deal activity for strategic partnership...

Helping to Ensure Success After the Deal

One of my favorite places to hang out in Tokyo is the Apple Store in the Ginza area.  It is a beautiful four-story venue, complete with a theater (where one can sit and receive non-stop sessions on all of Apple’s products) and, of course, the Genius Bar.  One of the...

The Best Buyers Are The Best Sellers

As it is often necessary to structure creative deals with deferred and/or ongoing value delivered to the seller, an important but frequently overlooked component of the deal process is to position your company as the ideal partner for the acquired asset. Recently, the...

Maintaining Deal Momentum in the Summertime

Fresh off Memorial Day Weekend, I had to face the reality that summer is here! When the kids are out of school, the regular schedules that we have enjoyed throughout the year become replaced by a multitude of summer camps, travels, and family fun. But as we know,...

Looking at Deal Value Beyond the Headlines

The press release is the public’s first (and oftentimes only) view into the details of a transaction.  However, while the press release is the victory lap of a transaction process, it rarely  provides the full details of the transaction.  Sure, it provides basic...

Companies are bought, because they are sold

Every entrepreneur hopes that if they build it, someday someone will come knocking at their door with a large check. But what does it take to get someone to knock on that door? And, how do you make sure your caller actually has a large check? Selling. Companies are...

Almost five years in the making…

The arrival of new regulations in the EU has been one of the hottest topics in the medical device space over the past several years.  They were first proposed in 2012 and are finally here in 2017.  The new regulations were aimed at three main goals: Improve the...

Finding the Right Partner

You’re ready to sell. Term sheets are on the table. Deal structure, terms, and timing are being highly scrutinized and negotiated back and forth. In determining the optimal deal, however, something that isn’t clearly delineated in term sheets might be the largest...

Biotalk, Episode 3: Roger Longman, Real Endpoints

In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making....

Q1 2017 Trends in Biotech Finance

Our Q1 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: Biopharma public indices Biopharma IPOs Deal activity for strategic partnership...